What analysts think of Novo, Him & Hers after obesity pill withdrawal
Novo Nordisk’s Denmark-listed shares climbed more than 7%, while the stock gained close to 6% in US premarket trading after telehealth company Hims & Hers said it would stop offering its newly launched oral obesity pill copycat following regulatory scrutiny. Hims & Hers, by contrast, fell nearly 20% in premarket trading. Additionally, Novo Nordisk also
